Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 0464 • ACR Convergence 2022
JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review
Diana Prieto-Peña¹, Javier Loricera², Susana Romero Yuste³, Anne Riveros-Frutos⁴, F. Javier Narváez⁵, Eugenio De Miguel⁶, Valentina Emperiale⁷, Elena Becerra-Fernández⁸, Santos Castañeda⁹, Eztizen Labrador¹⁰, Olga Maiz¹¹, Miguel Ángel González-Gay¹² and Ricardo Blanco², ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Complexo Hospitalario Universitario, Pontevedra, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, ⁸Hospital Universitario de Torrevieja, London, United Kingdom, ⁹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ¹⁰Hospital San Pedro, Logroño, Spain, ¹¹Hospital Universitario de Donostia, San Sebastián, Spain, ¹²Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Giant Cell Arteritis (GCA) may be refractory to standard treatment with glucocorticoids and conventional and/or biologic disease-modifying antirheumatic drugs (cDMARDs/bDMARDs). The JAK/STAT signaling pathway…
Abstract Number: 0559 • ACR Convergence 2022
JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Signaling Cascade in Minor Salivary Gland Mesenchymal Stromal Cells
Ilya Gurevic, jacques Galipeau and Sara McCoy, University of Wisconsin, Madison, WI
Background/Purpose: Sjögren's Disease (SjD) has high glandular IFNg levels, associated with disease activity and lymphoma risk. We previously showed IFNg-stimulated minor salivary gland (SG)-mesenchymal stromal…
Abstract Number: 0584 • ACR Convergence 2022
Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways
Brandon Johnson, Jennifer Koenitzer, Peter Schafer and Ian M. Catlett, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib is a selective inhibitor of tyrosine kinase 2 (TYK2) that has shown clinical efficacy in psoriasis, PsA, and SLE. Deucravacitinib is an allosteric…
Abstract Number: 0652 • ACR Convergence 2022
Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway
Shohei Nakamura, Yuko okamoto, Yasuhiro Katsumata and Masayoshi Harigai, Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced…
Abstract Number: 0653 • ACR Convergence 2022
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
Hiroshi Kajiyama¹, Yoshimi Aizaki², Hiroaki Yazawa³, Kazuhiro Yokota³, Yasuto Araki², Yuji Akiyama² and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Hydroxychloroquine (HCQ) is an anti-malarial medicine and an immunomodulator to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical…
Abstract Number: 0714 • ACR Convergence 2022
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Serostatus may be associated with different responses to treatment with biologic disease-modifying anti-rheumatic drugs (DMARD) or Janus kinase inhibitors (JAKi) in patients with rheumatoid…
Abstract Number: 0723 • ACR Convergence 2022
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Lea Hoisnard¹, Laura Pina Vegas², Rosemary Dray-Spira³, Alain Weill³, Mahmoud Zureik³ and Emilie sbidian⁴, ¹Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France, ²Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France, ⁴Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
Background/Purpose: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib…
Abstract Number: 0753 • ACR Convergence 2022
Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
Koichi Sugihara¹, Risa Wakiya¹, Tomohiro Kameda¹, Hiromi Shimada¹, Shusaku nakashima¹, Mikiya Kato¹, Taichi Miyagi¹, mao mizusaki², Rina Mino¹ and Hiroaki Dobashi³, ¹Kagawa University, Miki-cho, Kita-gun, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan
Background/Purpose: BNT162b2 is the most commonly used COVID-19 vaccine in Japan. The safety and efficacy of the vaccine was demonstrated in the general population, but…
Abstract Number: 0771 • ACR Convergence 2022
The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
Fanny De La Fuente¹, Rakiba Belkhir², Julien Henry³, Chi Duc Nguyen⁴, Thao Pham⁵, Vincent GERMAIN⁶, Pierre-Edouard Gavand⁷, Céline Labadie¹, Claire Brière⁸, Ambre Lauret⁸, Thierry Cardon⁹, Gaël Mouterde¹⁰, Isabelle Bonnet¹¹, Léa Rouxel¹², Marie Truchetet¹, Thierry schaeverbeke¹³, Christophe Richez¹⁴ and Marie Kostine¹⁵, ¹Bordeaux University Hospital, Bordeaux, France, ²Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ³Department of Rheumatology, University Paris-Saclay, Hospital Bicêtre, Le Plessis Robinson, Ile-de-France, France, ⁴Bethune Hospital, Bethune, France, ⁵Aix-Marseille univ, APHM, Marseille, France, ⁶Pau Hospital, Rheumatology, Pau, France, Pau, France, ⁷Rhena Clinic, Strasbourg, France, ⁸Intercommunal Creteil Hospital, Créteil, France, ⁹Lille University Hospital, Lille, France, ¹⁰Lapeyronie Hospital, Montpellier, France, ¹¹University Paris-Saclay, Hospital Bicêtre, Bicêtre, France, ¹²Arcachon Hospital, Arcachon, France, ¹³CHU de Bordeaux, Bordeaux, France, ¹⁴Université de Bordeaux, Bordeaux, France, ¹⁵Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France
Background/Purpose: Rheumatic immune related adverse events (irAEs) are observed in about 5 to 10% of cancer patients receiving checkpoint inhibitors (ICIs), with inflammatory arthritis (IA)…
Abstract Number: 0909 • ACR Convergence 2022
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Maria Luque-Tevar³, Pilar Font¹, Montserrat Romero-Gomez², Desiree Ruiz-Vilchez⁴, Sara Remuzgo-Martinez⁵, Raquel Lopez Mejias⁶, María Carmen Ábalos-Aguilera⁷, Rafaela Ortega-Castro¹, José Perez-Venegas⁸, Mª Dolores Ruiz-Montesinos⁸, Carmen Dominguez⁸, Carlos Rodriguez-Escalera⁹, Carmen Romero-Barco⁹, Antonio Fernandez-Nebro¹⁰, Natalia Mena Vazquez¹⁰, Jose Luis Marenco¹¹, Julia Uceda Montañez¹¹, Charo Santos¹², Nuria Barbarroja¹, Mª Angeles Aguirre¹³, Alejandro Escudero-Contreras², Eduardo Collantes¹, Miguel Ángel González-Gay¹⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³IMIBIC, Córdoba, Spain, ⁴Reina Sofia University Hospital, Cordoba, Cordoba, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶IDIVAL, Santander, Spain, ⁷Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁸Virgen Macarena University Hospital, Sevilla, Spain, ⁹Virgen de la Victoria Hospital, Málaga, Spain, ¹⁰Regional University Hospital of Málaga, Málaga, Spain, ¹¹Virgen de Valme University Hospital, Sevilla, Spain, ¹²Virgen de Valme University Hospital, Málaga, Spain, ¹³Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…
Abstract Number: 1275 • ACR Convergence 2022
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
Sana Kang¹, George Gennaoui² and J. Patricia Dhar³, ¹Ascension St John Hospital, Chesterfield, MO, ²Ascension St. John Hospital, St. Clair Shores, MI, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: The US Center for Disease Control and Prevention recommends that adults ages 19 years and older, with immunocompromising conditions should receive a dose of…
Abstract Number: 1588 • ACR Convergence 2022
Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Use of Adalimumab in Patients with Rheumatoid Arthritis
Dimitrios Pappas¹, Jacqueline O'Brien², Lin Guo², Ying Shan², Joshua Baker³, Greg Kricorian⁴, Scott Stryker⁵ and David Collier⁶, ¹Corrona Research Foundation; CorEvitas, LLC, Albany, NY, ²CorEvitas, LLC, Waltham, MA, ³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., San Francisco, CA, ⁶Amgen Inc., Simi Valley, CA
Background/Purpose: It is unclear whether a patient with rheumatoid arthritis (RA) whose disease fails to respond to 1 drug in a therapeutic class should switch…
Abstract Number: 1648 • ACR Convergence 2022
Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Eiichi Tanaka¹, Ryoko Sakai², Eisuke Inoue³ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Meiji Pharmaceutical University, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, concerns have been raised about the risk of…
Abstract Number: 1700 • ACR Convergence 2022
IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease
Jieqiong Li¹ and Wen Zhang², ¹Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To explore the phenotype and role of gamma delta (γδ) T cells in the pathogenesis of IgG4-related disease (IgG4-RD), focusing on the effect on…
Abstract Number: 1737 • ACR Convergence 2022
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner¹, Ulvi Ahmadov¹, Morten Aagaard Nielsen², Lasse Sommer Kristensen¹ and Tue Kragstrup³, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, and Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].